Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etentamig - Abbvie/Amgen

Next Previous
Search
Drug Profile

Etentamig - Abbvie/Amgen

Alternative Names: ABBV-383; Etentamig-Abbvie/Amgen; TNB-383B

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TeneoBio; TeneoOne
  • Developer AbbVie; TeneoOne
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase I/II Amyloid light-chain amyloidosis

Most Recent Events

  • 25 Mar 2025 AbbVie plans a phase I trial for Multiple Myeloma (Monotherapy, Combination-therapy) in June 2025 (IV, Infusion) (NCT06892522)
  • 11 Feb 2025 TNB 3838 is still in phase I/II trials in Multiple-myeloma (Second-line therapy or greater) in Germany and USA (IV, Injection) (NCT03933735)
  • 07 Dec 2024 Adverse events and efficacy data from a phase I trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top